KIMS Approves ₹600 Crore Preferential Allotment of Warrants to Promoters
KIMS approved issuing 77.02 lakh warrants convertible into equity shares at ₹779 each to promoters for ₹599.99 crore. An EGM is scheduled for 09 July 2026 to seek shareholder approval. Warrants are exercisable within 18 months.
The preferential allotment of warrants to promoters for a substantial amount of nearly ₹600 crore can significantly impact the company's capital structure, financial leverage, and potentially its future earnings per share upon conversion. It also signals strong promoter commitment.
The company is raising a significant amount of capital through preferential allotment of warrants to its promoters, which is generally viewed positively as it strengthens the company's financial position and demonstrates promoter confidence.
Krishna Institute of Medical Sciences Limited (KIMS) announced that its Board of Directors, in a meeting held on Saturday, 13 June 2026, approved the preferential allotment of warrants to members of the promoter and promoter group. The company will issue 77,02,182 warrants, each fully convertible into one equity share of ₹2 face value, at a price of ₹779 per warrant. This preferential allotment, subject to shareholder and regulatory approvals, will be on a private placement basis and will aggregate to ₹599.99 crore (₹5,99,99,99,778). The allottees include Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP.
The warrants can be exercised in one or more tranches within 18 months from the date of allotment. A payment of 25% of the warrant issue price is due at the time of allotment, with the remaining 75% payable upon exercise. The relevant date for determining the warrant issue price was Tuesday, 09 June 2026.
Furthermore, the Board approved convening an Extra-Ordinary General Meeting (EGM) of shareholders on 09 July 2026, to seek necessary approvals for these matters. The meeting of the Board of Directors commenced at 10:30 AM and concluded at 12:45 PM.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.